Global CNS Lymphoma Market- Industry Analysis, Growth, Segmentation and Forecast-2020-2026



Global CNS Lymphoma Market was valued $xx Mn in 2019 and is expected to reach $xx Mn by 2026, at a CAGR of xx%.


Global CNS Lymphoma Market: Introduction

Central nervous system lymphoma is an extra nodal non-Hodgkin lymphoma (NHL) that is confined to the brain, leptomeninges, eyes, or spinal cord. CNS lymphoma is a rare malignancy, comprising only 2% of primary CNS tumours in the United States. The annual incidence of primary CNS lymphoma in the United States is approximately 1,400 cases; this is steadily increasing as the population ages. A similarly higher incidence is seen in Caucasians compared with African Americans. The incidence in Hispanics appears to be similar to that in non-Hispanics.

Global CNS Lymphoma: Market Dynamics

The past decade has witnessed an acceleration in progress in central nervous system (CNS) lymphoma research. Key insights were made into its molecular pathophysiology, yielding advances in molecular and genetic diagnosis, prognostication, and implementation of innovative experimental approaches. Anti-CD20 antibody–based immunotherapy has become a cornerstone of treatment. The market is expected to be majorly driven by the rising prevalence of primary CNS lymphoma, increasing awareness regarding the advanced technologies in the market, and rising governmental spending on healthcare. The demand for diagnostic methods is on the surge; thus, propelling the demand for CNS lymphoma treatment across the regions.

Global CNS Lymphoma Market: Segment Analysis

By treatment segment is expected to drive the CNS Lymphoma Market

The treatment segment is expected to grow at a CAGR of xx% during the forecast period. The increasing incidences of lymphoma are driving the market growth. Chemotherapy plays the most important role in the treatment of PCNSL. MTX, the most widely used drug for PCNSL, is a folate antagonist that interrupts DNA synthesis.

Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer. Because primary CNS lymphoma spreads throughout the brain, external radiation therapy is given to the whole brain. RT covering both the whole brain and posterior orbits, termed whole-brain radiotherapy (WBRT), is the most frequently utilized approach because of the potential for out-of-field failures. Current research is focusing on reducing the risk of neurotoxicity from RT without compromising long-term disease control.

Hospital segment expected to grow at a faster pace owing to the increased treatment processes.

By end-use, the hospital segment is expected to register a CAGR of xx% during the forecast period. Hospitals held a leading revenue share of xx% in the Lymphoma Market in 2020. Surgeries and other operations are performed majorly in hospitals, due to availability of all tools and technologies required. Treatment procedures conducted in hospitals or hospital-attached outpatient facilities enable ease of handling any emergency situations that may arise.

Global CNS Lymphoma Market

To Know About The Research Methodology :- Request Free Sample Report

Global CNS Lymphoma Market: Regional Analysis

 

Global CNS Lymphoma Market1

North America accounted for the largest share of xx% in 2019, reason being the rising prevalence of cancer associated lymphedema. Growth in insurance coverage in the U.S. has increased the burden on the country’s healthcare system, which has highlighted the need for improving efficiency and management of work in North America. Well-established healthcare infrastructure, ease of availability is also a key driver affecting the market growth. Investments by key players in this field has boosted the market growth. Rising adoption of technologically advanced diagnostic imaging systems for lymphedema is rapidly growing the market.

Asia Pacific is also expected to witness significant growth during the forecast period due to the increasing geriatric population and rising health care expenditures. The allocation of a large amount of healthcare expenditure for hospitals and dispensing medicines to the elderly is expected drive the market demand.

Scope of Report Global CNS Lymphoma Market:  Inquire before buying

Global CNS Lymphoma Market2

Global CNS Lymphoma Market: By Region

• North America
• Europe
• South America
• MEA
• Asia Pacific

Global CNS Lymphoma Market: Key Players

• Amgen
• Dr. Reddy’s Laboratories
• Roche
• Bristol-Myers Squibb
• Cipla
• Merck
• Gilead Science
• Novartis
• AbbVie
• Fresenius SE & Co
• KGaA
• Sanofi S.A
• Celgene Corp
• Johnson & Johnson

Recent Development:

Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company, has announced that it hasentered into a collaboration with Dana-Farber Cancer Institute (DFCI) in the United States, to investigate the use of Kazia's investigational new drug, paxalisib (formerly GDC-0084), in primary central nervous system (CNS) lymphoma, a potential new indication for the drug. 





Global CNS Lymphoma Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources

3. Executive Summary: CNS Lymphoma Market Size, By Market Value (US$ Mn)

4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies

5. Supply Side and Demand Side Indicators

6. Global CNS Lymphoma Market Analysis and Forecast
6.1. CNS Lymphoma Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global CNS Lymphoma Market Analysis and Forecast, By Treatment
7.1. Introduction and Definition
7.2. Key Findings
7.3. CNS Lymphoma Market Value Share Analysis, By Treatment
7.4. CNS Lymphoma Market Size (US$ Mn) Forecast, By Treatment
7.5. CNS Lymphoma Market Analysis, By Treatment
7.6. CNS Lymphoma Market Attractiveness Analysis, By Treatment

8. Global CNS Lymphoma Market Analysis and Forecast, By Application
8.1. Introduction and Definition
8.2. Key Findings
8.3. CNS Lymphoma Market Value Share Analysis, By Application
8.4. CNS Lymphoma Market Size (US$ Mn) Forecast, By Application
8.5. CNS Lymphoma Market Analysis, By Application
8.6. CNS Lymphoma Market Attractiveness Analysis, By Application

9. Global CNS Lymphoma Market Analysis, By Region
9.1. CNS Lymphoma Market Value Share Analysis, By Region
9.2. CNS Lymphoma Market Size (US$ Mn) Forecast, By Region
9.3. CNS Lymphoma Market Attractiveness Analysis, By Region

10. North America CNS Lymphoma Market Analysis
10.1. Key Findings
10.2. North America CNS Lymphoma Market Overview
10.3. North America CNS Lymphoma Market Value Share Analysis, By Treatment
10.4. North America CNS Lymphoma Market Forecast, By Treatment
10.4.1. Chemotherapy
10.4.2. Radiation Therapy
10.4.3. Steroid Therapy
10.4.4. Targeted Therapy
10.5. North America CNS Lymphoma Market Value Share Analysis, By Application
10.6. North America CNS Lymphoma Market Forecast, By Application
10.6.1. Hospitals
10.6.2. Clinics
10.6.3. Ambulatory Surgical Centers and Others
10.7. North America CNS Lymphoma Market Value Share Analysis, By Country
10.8. North America CNS Lymphoma Market Forecast, By Country
10.8.1. U.S.
10.8.2. Canada
10.8.3. Mexico
10.9. North America CNS Lymphoma Market Analysis, By Country
10.10. U.S. CNS Lymphoma Market Forecast, By Treatment
10.10.1. Chemotherapy
10.10.2. Radiation Therapy
10.10.3. Steroid Therapy
10.10.4. Targeted Therapy
10.11. U.S. CNS Lymphoma Market Forecast, By Application
10.11.1. Hospitals
10.11.2. Clinics
10.11.3. Ambulatory Surgical Centers and Others
10.12. Canada CNS Lymphoma Market Forecast, By Treatment
10.12.1. Chemotherapy
10.12.2. Radiation Therapy
10.12.3. Steroid Therapy
10.12.4. Targeted Therapy
10.13. Canada CNS Lymphoma Market Forecast, By Application
10.13.1. Hospitals
10.13.2. Clinics
10.13.3. Ambulatory Surgical Centers and Others
10.14. Mexico CNS Lymphoma Market Forecast, By Treatment
10.14.1. Chemotherapy
10.14.2. Radiation Therapy
10.14.3. Steroid Therapy
10.14.4. Targeted Therapy
10.15. Mexico CNS Lymphoma Market Forecast, By Application
10.15.1. Hospitals
10.15.2. Clinics
10.15.3. Ambulatory Surgical Centers and Others
10.16. North America CNS Lymphoma Market Attractiveness Analysis
10.16.1. By Treatment
10.16.2. By Application
10.17. PEST Analysis
10.18. Key Trends
10.19. Key Developments

11. Europe CNS Lymphoma Market Analysis
11.1. Key Findings
11.2. Europe CNS Lymphoma Market Overview
11.3. Europe CNS Lymphoma Market Value Share Analysis, By Treatment
11.4. Europe CNS Lymphoma Market Forecast, By Treatment
11.4.1. Chemotherapy
11.4.2. Radiation Therapy
11.4.3. Steroid Therapy
11.4.4. Targeted Therapy
11.5. Europe CNS Lymphoma Market Value Share Analysis, By Application
11.6. Europe CNS Lymphoma Market Forecast, By Application
11.6.1. Hospitals
11.6.2. Clinics
11.6.3. Ambulatory Surgical Centers and Others
11.7. Europe CNS Lymphoma Market Value Share Analysis, By Country
11.8. Europe CNS Lymphoma Market Forecast, By Country
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Sweden
11.8.7. CIS countries
11.8.8. Rest of Europe
11.9. Germany CNS Lymphoma Market Forecast, By Treatment
11.9.1. Chemotherapy
11.9.2. Radiation Therapy
11.9.3. Steroid Therapy
11.9.4. Targeted Therapy
11.10. Germany CNS Lymphoma Market Forecast, By Application
11.10.1. Hospitals
11.10.2. Clinics
11.10.3. Ambulatory Surgical Centers and Others
11.11. U.K. CNS Lymphoma Market Forecast, By Treatment
11.11.1. Chemotherapy
11.11.2. Radiation Therapy
11.11.3. Steroid Therapy
11.11.4. Targeted Therapy
11.12. U.K. CNS Lymphoma Market Forecast, By Application
11.12.1. Hospitals
11.12.2. Clinics
11.12.3. Ambulatory Surgical Centers and Others
11.13. France CNS Lymphoma Market Forecast, By Treatment
11.13.1. Chemotherapy
11.13.2. Radiation Therapy
11.13.3. Steroid Therapy
11.13.4. Targeted Therapy
11.14. France CNS Lymphoma Market Forecast, By Application
11.14.1. Hospitals
11.14.2. Clinics
11.14.3. Ambulatory Surgical Centers and Others
11.15. Italy CNS Lymphoma Market Forecast, By Treatment
11.15.1. Chemotherapy
11.15.2. Radiation Therapy
11.15.3. Steroid Therapy
11.15.4. Targeted Therapy
11.16. Italy CNS Lymphoma Market Forecast, By Application
11.16.1. Hospitals
11.16.2. Clinics
11.16.3. Ambulatory Surgical Centers and Others
11.17. Spain CNS Lymphoma Market Forecast, By Treatment
11.17.1. Chemotherapy
11.17.2. Radiation Therapy
11.17.3. Steroid Therapy
11.17.4. Targeted Therapy
11.18. Spain CNS Lymphoma Market Forecast, By Application
11.18.1. Hospitals
11.18.2. Clinics
11.18.3. Ambulatory Surgical Centers and Others
11.19. Sweden CNS Lymphoma Market Forecast, By Treatment
11.19.1. Chemotherapy
11.19.2. Radiation Therapy
11.19.3. Steroid Therapy
11.19.4. Targeted Therapy
11.20. Sweden CNS Lymphoma Market Forecast, By Application
11.20.1. Hospitals
11.20.2. Clinics
11.20.3. Ambulatory Surgical Centers and Others
11.21. CIS countries CNS Lymphoma Market Forecast, By Treatment
11.21.1. Chemotherapy
11.21.2. Radiation Therapy
11.21.3. Steroid Therapy
11.21.4. Targeted Therapy
11.22. CIS countries CNS Lymphoma Market Forecast, By Application
11.22.1. Hospitals
11.22.2. Clinics
11.22.3. Ambulatory Surgical Centers and Others
11.23. Rest of Europe CNS Lymphoma Market Forecast, By Treatment
11.23.1. Chemotherapy
11.23.2. Radiation Therapy
11.23.3. Steroid Therapy
11.23.4. Targeted Therapy
11.24. Rest of Europe CNS Lymphoma Market Forecast, By Application
11.24.1. Hospitals
11.24.2. Clinics
11.24.3. Ambulatory Surgical Centers and Others
11.25. Europe CNS Lymphoma Market Attractiveness Analysis
11.25.1. By Application
11.25.2. By Treatment
11.26. PEST Analysis
11.27. Key Trends
11.28. Key Developments

12. Asia Pacific CNS Lymphoma Market Analysis
12.1. Key Findings
12.2. Asia Pacific CNS Lymphoma Market Overview
12.3. Asia Pacific CNS Lymphoma Market Value Share Analysis, By Treatment
12.4. Asia Pacific CNS Lymphoma Market Forecast, By Treatment
12.4.1. Chemotherapy
12.4.2. Radiation Therapy
12.4.3. Steroid Therapy
12.4.4. Targeted Therapy
12.5. Asia Pacific CNS Lymphoma Market Value Share Analysis, By Application
12.6. Asia Pacific CNS Lymphoma Market Forecast, By Application
12.6.1. Hospitals
12.6.2. Clinics
12.6.3. Ambulatory Surgical Centers and Others
12.7. Asia Pacific CNS Lymphoma Market Value Share Analysis, By Country
12.8. Asia Pacific CNS Lymphoma Market Forecast, By Country
12.8.1. China
12.8.2. India
12.8.3. Japan
12.8.4. South Korea
12.8.5. Australia
12.8.6. ASEAN
12.8.7. Rest of Asia Pacific
12.9. Asia Pacific CNS Lymphoma Market Analysis, By Country
12.10. China CNS Lymphoma Market Forecast, By Treatment
12.10.1. Chemotherapy
12.10.2. Radiation Therapy
12.10.3. Steroid Therapy
12.10.4. Targeted Therapy
12.11. China CNS Lymphoma Market Forecast, By Application
12.11.1. Hospitals
12.11.2. Clinics
12.11.3. Ambulatory Surgical Centers and Others
12.12. India CNS Lymphoma Market Forecast, By Treatment
12.12.1. Chemotherapy
12.12.2. Radiation Therapy
12.12.3. Steroid Therapy
12.12.4. Targeted Therapy
12.13. India CNS Lymphoma Market Forecast, By Application
12.13.1. Hospitals
12.13.2. Clinics
12.13.3. Ambulatory Surgical Centers and Others
12.14. Japan CNS Lymphoma Market Forecast, By Treatment
12.14.1. Chemotherapy
12.14.2. Radiation Therapy
12.14.3. Steroid Therapy
12.14.4. Targeted Therapy
12.15. Japan CNS Lymphoma Market Forecast, By Application
12.15.1. Hospitals
12.15.2. Clinics
12.15.3. Ambulatory Surgical Centers and Others
12.16. South Korea CNS Lymphoma Market Forecast, By Treatment
12.16.1. Chemotherapy
12.16.2. Radiation Therapy
12.16.3. Steroid Therapy
12.16.4. Targeted Therapy
12.17. South Korea CNS Lymphoma Market Forecast, By Application
12.17.1. Hospitals
12.17.2. Clinics
12.17.3. Ambulatory Surgical Centers and Others
12.18. Australia CNS Lymphoma Market Forecast, By Treatment
12.18.1. Chemotherapy
12.18.2. Radiation Therapy
12.18.3. Steroid Therapy
12.18.4. Targeted Therapy
12.19. Australia CNS Lymphoma Market Forecast, By Application
12.19.1. Hospitals
12.19.2. Clinics
12.19.3. Ambulatory Surgical Centers and Others
12.20. ASEAN CNS Lymphoma Market Forecast, By Treatment
12.20.1. Chemotherapy
12.20.2. Radiation Therapy
12.20.3. Steroid Therapy
12.20.4. Targeted Therapy
12.21. ASEAN CNS Lymphoma Market Forecast, By Application
12.21.1. Hospitals
12.21.2. Clinics
12.21.3. Ambulatory Surgical Centers and Others
12.22. Rest of Asia Pacific CNS Lymphoma Market Forecast, By Treatment
12.22.1. Chemotherapy
12.22.2. Radiation Therapy
12.22.3. Steroid Therapy
12.22.4. Targeted Therapy
12.23. Rest of Asia Pacific CNS Lymphoma Market Forecast, By Application
12.23.1. Hospitals
12.23.2. Clinics
12.23.3. Ambulatory Surgical Centers and Others
12.24. Asia Pacific CNS Lymphoma Market Attractiveness Analysis
12.24.1. By Treatment
12.24.2. By Application
12.25. PEST Analysis
12.26. Key Trends
12.27. Key Developments

13. Middle East & Africa CNS Lymphoma Market Analysis
13.1. Key Findings
13.2. Middle East & Africa CNS Lymphoma Market Overview
13.3. Middle East & Africa CNS Lymphoma Market Value Share Analysis, By Treatment
13.4. Middle East & Africa CNS Lymphoma Market Forecast, By Treatment
13.4.1. Chemotherapy
13.4.2. Radiation Therapy
13.4.3. Steroid Therapy
13.4.4. Targeted Therapy
13.5. Middle East & Africa CNS Lymphoma Market Value Share Analysis, By Application
13.6. Middle East & Africa CNS Lymphoma Market Forecast, By Application
13.6.1. Hospitals
13.6.2. Clinics
13.6.3. Ambulatory Surgical Centers and Others
13.7. Middle East & Africa CNS Lymphoma Market Value Share Analysis, By Country
13.8. Middle East & Africa CNS Lymphoma Market Forecast, By Country
13.8.1. GCC Countries
13.8.2. South Africa
13.8.3. Nigeria
13.8.4. Egypt
13.8.5. Rest of Middle East & Africa
13.9. Middle East & Africa CNS Lymphoma Market Analysis, By Country
13.10. GCC Countries CNS Lymphoma Market Forecast, By Treatment
13.10.1. Chemotherapy
13.10.2. Radiation Therapy
13.10.3. Steroid Therapy
13.10.4. Targeted Therapy
13.11. GCC Countries CNS Lymphoma Market Forecast, By Application
13.11.1. Hospitals
13.11.2. Clinics
13.11.3. Ambulatory Surgical Centers and Others
13.12. South Africa CNS Lymphoma Market Forecast, By Treatment
13.12.1. Chemotherapy
13.12.2. Radiation Therapy
13.12.3. Steroid Therapy
13.12.4. Targeted Therapy
13.13. South Africa CNS Lymphoma Market Forecast, By Application
13.13.1. Hospitals
13.13.2. Clinics
13.13.3. Ambulatory Surgical Centers and Others
13.14. Nigeria CNS Lymphoma Market Forecast, By Treatment
13.14.1. Chemotherapy
13.14.2. Radiation Therapy
13.14.3. Steroid Therapy
13.14.4. Targeted Therapy
13.15. Nigeria CNS Lymphoma Market Forecast, By Application
13.15.1. Hospitals
13.15.2. Clinics
13.15.3. Ambulatory Surgical Centers and Others
13.16. Egypt CNS Lymphoma Market Forecast, By Treatment
13.16.1. Chemotherapy
13.16.2. Radiation Therapy
13.16.3. Steroid Therapy
13.16.4. Targeted Therapy
13.17. Egypt CNS Lymphoma Market Forecast, By Application
13.17.1. Hospitals
13.17.2. Clinics
13.17.3. Ambulatory Surgical Centers and Others
13.18. Rest of Middle East & Africa CNS Lymphoma Market Forecast, By Treatment
13.18.1. Chemotherapy
13.18.2. Radiation Therapy
13.18.3. Steroid Therapy
13.18.4. Targeted Therapy
13.19. Rest of Middle East & Africa CNS Lymphoma Market Forecast, By Application
13.19.1. Hospitals
13.19.2. Clinics
13.19.3. Ambulatory Surgical Centers and Others
13.20. Middle East & Africa CNS Lymphoma Market Attractiveness Analysis
13.20.1. By Treatment
13.20.2. By Application
13.21. PEST Analysis
13.22. Key Trends
13.23. Key Developments

14. South America CNS Lymphoma Market Analysis
14.1. Key Findings
14.2. South America CNS Lymphoma Market Overview
14.3. South America CNS Lymphoma Market Value Share Analysis, By Treatment
14.4. South America CNS Lymphoma Market Forecast, By Treatment
14.4.1. Chemotherapy
14.4.2. Radiation Therapy
14.4.3. Steroid Therapy
14.4.4. Targeted Therapy
14.5. South America CNS Lymphoma Market Value Share Analysis, By Application
14.6. South America CNS Lymphoma Market Forecast, By Application
14.6.1. Hospitals
14.6.2. Clinics
14.6.3. Ambulatory Surgical Centers and Others
14.7. South America CNS Lymphoma Market Value Share Analysis, By Country
14.8. South America CNS Lymphoma Market Forecast, By Country
14.8.1. Brazil
14.8.2. Colombia
14.8.3. Argentina
14.8.4. Rest of South America
14.9. South America CNS Lymphoma Market Analysis, By Country
14.10. Brazil CNS Lymphoma Market Forecast, By Treatment
14.10.1. Chemotherapy
14.10.2. Radiation Therapy
14.10.3. Steroid Therapy
14.10.4. Targeted Therapy
14.11. Brazil CNS Lymphoma Market Forecast, By Application
14.11.1. Hospitals
14.11.2. Clinics
14.11.3. Ambulatory Surgical Centers and Others
14.12. Colombia CNS Lymphoma Market Forecast, By Treatment
14.12.1. Chemotherapy
14.12.2. Radiation Therapy
14.12.3. Steroid Therapy
14.12.4. Targeted Therapy
14.13. Colombia CNS Lymphoma Market Forecast, By Application
14.13.1. Hospitals
14.13.2. Clinics
14.13.3. Ambulatory Surgical Centers and Others
14.14. Argentina CNS Lymphoma Market Forecast, By Treatment
14.14.1. Chemotherapy
14.14.2. Radiation Therapy
14.14.3. Steroid Therapy
14.14.4. Targeted Therapy
14.15. Argentina CNS Lymphoma Market Forecast, By Application
14.15.1. Hospitals
14.15.2. Clinics
14.15.3. Ambulatory Surgical Centers and Others
14.16. Rest of South America CNS Lymphoma Market Forecast, By Treatment
14.16.1. Chemotherapy
14.16.2. Radiation Therapy
14.16.3. Steroid Therapy
14.16.4. Targeted Therapy
14.17. Rest of South America CNS Lymphoma Market Forecast, By Application
14.17.1. Hospitals
14.17.2. Clinics
14.17.3. Ambulatory Surgical Centers and Others
14.18. South America CNS Lymphoma Market Attractiveness Analysis
14.18.1. By Treatment
14.18.2. By Application
14.19. PEST Analysis
14.20. Key Trends
14.21. Key Developments

15. Company Profiles
15.1. Market Share Analysis, By Company
15.2. Competition Matrix

15.2.1. Competitive Benchmarking of key players By price, presence, market share, Application, and R&D investment
15.2.2. New Product Launches and Product Enhancements
15.2.3. Market Consolidation
15.2.3.1. M&A By Regions, Investment and Application
15.2.3.2. M&A Key Players, Forward Integration and Backward Integration

15.3. Company Profiles: Key Players
15.3.1. Amgen
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategy
15.3.1.5. Recent Developments
15.3.1.6. Development Footprint
15.3.2. Dr. Reddy’s Laboratories
15.3.3. Roche
15.3.4. Bristol-Myers Squibb
15.3.5. Cipla
15.3.6. Merck
15.3.7. Gilead Science
15.3.8. Novartis
15.3.9. AbbVie
15.3.10. Fresenius SE & Co
15.3.11. KGaA
15.3.12. Sanofi S.A
15.3.13. Celgene Corp
15.3.14. Johnson & Johnson
15.3.15. Others

16. Primary Key Insights
  • INQUIRE BEFORE BUYING